Synonyms: CDP-323 | CDP323
Compound class:
Synthetic organic
Comment: Zaurategrast (CDP-323) is a small molecule inhibitor of α4-containing integrin complexes that was developed by Celltech [3]. It was intended as a new oral drug treatment for multiple sclerosis [2]. Zaurategrast has the same mechanism of action as the approved MS therapeutic natalizumab. Zaurategrast is an ester prodrug whose active entity is CT7758 [1].
|
|
References |
1. Chanteux H, Staelens L, Mancel V, Gerin B, Boucaut D, Prakash C, Nicolas JM. (2015)
Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos, 43 (9): 1381-91. [PMID:26153275] |
2. Davenport RJ, Munday JR. (2007)
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?. Drug Discov Today, 12 (13-14): 569-76. [PMID:17631252] |
3. Li H, Huang SY, Shi FH, Gu ZC, Zhang SG, Wei JF. (2018)
α4β7 integrin inhibitors: a patent review. Expert Opin Ther Pat, 28 (12): 903-917. [PMID:30444683] |
4. Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, Bennett B. (2013)
Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. PLoS One, 8 (3): e58438. [PMID:23472197] |